ASH 2023 | Utilizing PET/CT to improve staging in extranodal marginal zone lymphoma
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, speaks on a study which aimed to determine the ability of PET/CT to detect fluorodeoxyglucose (FDG)-avid extranodal marginal zone lymphoma (EMZL) during staging work-up. Data from this study, which was the most extensive analysis evaluating the accuracy of PET/CT to determine initial tumor burden in EMZL, suggest that the current Lugano classification guidelines should be revised to include PET/CT in the staging of EMZL patients, as it is a largely FDG-avid disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Genmab, ADC Therapeutics, BeiGene
Consultancy: Abbvie, ADC Therapeutics, Genentech, Regeneron
